EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient

Davide Lo Porto, Alessandra Mularoni iD, Elio Castagnola iD, Carolina Saffioti

Transplant Infectious Disease · 2023

DOI: 10.1111/tid.14159 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Davide Lo Porto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, IRCCS-ISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Clostridium Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile (CD) is one of the most important causes of diarrhea in hospitalized patients, in particular those who undergo an allogeneic hematopoietic cell transplant (allo‐HCT) and who are more at risk of developing a CD infection (CDI) due to frequent hospitalizations, iatrogenic immunosuppression, and prolonged antibiotic cycles. CDI may represent a severe condition in allo‐HCT patients, increasing the length of hospitalization, influencing the intestinal microbiome with a bidirectional association with graft‐versus‐host disease, and leading to unfavorable outcomes, including death. The diagnosis of CDI requires the exclusion of other probable causes of diarrhea in HCT patients and is based on highly sensitive and highly specific tests to distinguish colonization from infection. In adult patients, fidaxomicin is recommended as first‐line, with oral vancomycin as an alternative agent. Bezlotoxumab may be used to reduce the risk of recurrence. In pediatric patients, vancomycin and metronidazole are still suggested as first‐line therapy, but fidaxomicin will probably become standard in pediatrics in the near future. Because of insufficient safety data, fecal microbiota transplantation is not routinely recommended in HCT in spite of promising results for the management of recurrences in other populations. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationClostridium InfectionsAdultHumansChildVancomycinFidaxomicinTransplant RecipientsAnti-Bacterial AgentsDiarrhea

Stichwörter der Autor:innen

Clostridioides difficile infectionallogeneic hematopoietic cell transplantationfecal microbiota transplantationrecurrent Clostridioides difficile infection

Substanzen

VancomycinFidaxomicinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Unit of Infectious Diseases, IRCCS-ISMETT Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, Palermo, Italy.
  • Pediatric Infectious Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

ORCID-Profile: Alessandra Mularoni, Elio Castagnola

Förderung

  • Italian Ministry of Health

Zitieren

APA

Lo Porto, D., Mularoni, A., Castagnola, E., & Saffioti, C. (2023). Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient. Transplant Infectious Disease. https://doi.org/10.1111/tid.14159

Vancouver

Lo Porto D, Mularoni A, Castagnola E, Saffioti C. Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient. Transplant Infectious Disease. 2023. doi:10.1111/tid.14159

BibTeX
@article{LoPorto2023,
  author = {Lo Porto, Davide and Mularoni, Alessandra and Castagnola, Elio and Saffioti, Carolina},
  title = {Clostridioides difficile infection in the allogeneic hematopoietic cell transplant recipient},
  journal = {Transplant Infectious Disease},
  year = {2023},
  doi = {10.1111/tid.14159}
}
Kostenlos starten →